Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era

Niu, Xiaoshuang; Xue, Fen; Liu, Peiyao; Hu, Chaosu; He, Xiayun

doi:10.7150/ijms.68394



Theranostics

International Journal of Biological Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Med Sci 2022; 19(2):267-273. doi:10.7150/ijms.68394 This issue Cite

Research Paper

Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era

Xiaoshuang Niu^1,2,3, Fen Xue^1,2,3, Peiyao Liu^1,2,3, Chaosu Hu^1,2,3, Xiayun He^1,2,3✉

1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
3. Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China

Citation:

Niu X, Xue F, Liu P, Hu C, He X. Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era. Int J Med Sci 2022; 19(2):267-273. doi:10.7150/ijms.68394. https://www.medsci.org/v19p0267.htm

Other styles

Abstract

Objectives: To evaluate long-term outcomes and late toxicities of nasopharyngeal carcinoma (NPC) patients with T1-2N0-3M0 stage in intensity-modulated radiotherapy (IMRT) era.

Materials and Methods: From June 2005 to October 2013, 276 patients confirmed T1-2N0-3M0 NPC treated with IMRT were reviewed, with 143 (51.8%) N0-1 disease and 133 (48.2%) N2‐3 disease. Among them, 76.4% received chemotherapy. The prescribed doses given to the primary tumor and lymph nodes were 66Gy in 30 fractions.

Results: After a median follow-up of 103 months, the 5-year and 10-year overall survival (OS) were 90.6% and 79.2%. The 5-year and 10-year local control (LC) rate, regional control (RC) rate and distant metastasis free survival (DMFS) were 97.0% and 91.9%, 94.1% and 92.2%, 89.4% and 87.0%, respectively. The 5-year and 10-year OS, RC rate and DMFS of N0-1 compared with those of N2-3 were 98.6% vs. 82.0% and 86.8% vs. 70.9% (P=0.000), 99.3% vs. 88.3% and 99.3% vs. 84.1% (P=0.000), 97.9% vs. 80.1% and 95.7% vs. 77.5% (P=0.000). The incidence of 3-4 late toxicities were low and mainly xerostomia and hearing deficit. The rates of radiation-induced cranial nerve palsy and temporal necrosis were 2.5% and 2.5%, respectively. Eighteen patients had the second primary tumor, of whom eight were lung cancer, six were head and neck cancer, four were others.

Conclusions: Satisfactory locoregional control was achieved in T1‐2N0-3M0 NPC treated with IMRT. Distant metastasis was the main failure cause and N2-3 was the main adverse prognostic factor. Second primary tumor occurred 6.5% and negatively impacted OS in NPC.

Keywords: nasopharyngeal carcinoma, T1-2, long-term outcomes, intensity-modulated radiotherapy

Citation styles

APA

Niu, X., Xue, F., Liu, P., Hu, C., He, X. (2022). Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era. International Journal of Medical Sciences, 19(2), 267-273. https://doi.org/10.7150/ijms.68394.

ACS

Niu, X.; Xue, F.; Liu, P.; Hu, C.; He, X. Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era. Int. J. Med. Sci. 2022, 19 (2), 267-273. DOI: 10.7150/ijms.68394.

NLM

CSE

Niu X, Xue F, Liu P, Hu C, He X. 2022. Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era. Int J Med Sci. 19(2):267-273.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.